Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
to Section 16. Form 4 or Form 5		
obligations may continue. See		

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Butch Jason						2. Issuer Name and Ticker or Trading Symbol AGILE THERAPEUTICS INC [AGRX]									k all app Direc	tionship of Reportir all applicable) Director Officer (give title		ng Person(s) to Issuer 10% Owner Other (spec	
(Last)	(Fir	,	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/26/2021										belov			below)	, ,
(Street) PRINCE (City)			8540 Zip)		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line)	Form	or Joint/Group Filing (Check Applicable In filed by One Reporting Person In filed by More than One Reporting			
(Oity)	(00			n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benefi	icially	/ Own	ed			
1. Title of Security (Instr. 3)			2. Transaction Date		2A. Exe	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3,) or 5. Amo 4 and Securing Benefic		unt of ties cially Following	Forn (D) c	wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount	(A) (D)	or Pr	ice	Transa	ction(s) 3 and 4)			(Instr. 4)		
Common Stock			03/26/	5/2021				P		8,642	A	\$	2.01	18,642			D		
Common Stock 03			03/29/	′2021				P		1,358	A	\$	1.99	99 20,000			D		
		Tal									osed of, o				Owne	d			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) Execution Date, if any			on Date,	4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In	rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amour or Number of Shares	er						

Explanation of Responses:

/s/ Jason Butch

03/30/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).